CDD-1653

CDD-1653 is a potent and selective BMPR2 inhibitor (IC50=2.8 nM) . CDD-1653 reduces the ability of ATP to bind to the kinase domain of BMPR2, thereby affecting the phosphorylation of SMAD1/5/8 transcription factors, which play a key role in the BMP signaling pathway. CDD-1653 can be used to study diseases related to the BMP signaling pathway[1].

Product Specifications

CAS Number

[3034216-44-6]

UNSPSC

12352005

Target

TGF-β Receptor

Type

Reference compound

Related Pathways

TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Others

Assay Protocol

https://www.medchemexpress.com/cdd-1653.html

Concentration

10mM

Purity

99.38

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1N(CCN(C1)C2=NC(NC3=CC=CC(S(=O)(N)=O)=C3)=NC=C2OC)C4=CC=CC=C4

Molecular Formula

C21H22N6O4S

Molecular Weight

454.50

References & Citations

[1]Modukuri R K, et al. Discovery of highly potent and BMPR2-selective kinase inhibitors using DNA-encoded chemical library screening[J]. Journal of Medicinal Chemistry, 2023, 66 (3) : 2143-2160.